Souvik Saha

Dr. Souvik Saha

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in Journal of the ASEAN Federation of Endocrine Societies
Verified
Journal Article
Open access
PDF file
NDNiladri Das
Niladri Das
STSilima Subhasnigdha Tarenia
Silima Subhasnigdha Tarenia
SSSouvik Saha
Souvik Saha
PGPrashant Manohar Gaikwad
Prashant Manohar Gaikwad
DHDeep Kamlesh Hathi
Deep Kamlesh Hathi
NSNilanjan Sengupta
Nilanjan Sengupta
Primary growth hormone (GH) resistance or growth hormone insensitivity syndrome, also called Laron syndrome, is a hereditary disease caused by mutations in the GH receptor or in the post-receptor signaling pathway. This disorder is characterized by postnatal growth failure resembling GH deficiency. Differentiating the two conditions is necessary. We present the cases of two siblings, a 16-year-old female and a 9-year-old male, born from a consanguineous union. Both had normal birth weights with subsequent severe short stature and delayed teeth eruption, with no features suggestive of any systemic illness. Serum insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) were both low. Suspecting GH deficiency, provocative testing with clonidine was done revealing peak growth hormone >40 ng/mL in both patients. In view of low IGF1 and IGFBP3 and high GH on stimulation, IGF1 generation test was done for both siblings, with values supporting the diagnosis of GH insensitivity or Laron syndrome.

Verified
Journal Article
Open access
PDF file
SSSohini Samaddar
Sohini Samaddar
DBDaniel Buckles
Daniel Buckles
SSSouvik Saha
Souvik Saha
QZQiuyang Zhang
Qiuyang Zhang
ABAjay Bansal
Ajay Bansal
Esophageal adenocarcinoma (EAC) is a rapidly increasing lethal tumor. It commonly arises from a metaplastic segment known as Barrett’s esophagus (BE), which delineates the at-risk population. Ample research has elucidated the pathogenesis of BE and its progression from metaplasia to invasive carcinoma; and multiple molecular pathways have been implicated in this process, presenting several points of cancer interception. Here, we explore the mechanisms of action of various agents, including proton pump inhibitors, non-steroidal anti-inflammatory drugs, metformin, and statins, and explain their roles in cancer interception. Data from the recent AspECT trial are discussed to determine how viable a multipronged approach to cancer chemoprevention would be. Further, novel concepts, such as the repurposing of chemotherapeutic drugs like dasatinib and the prevention of post-ablation BE recurrence using itraconazole, are discussed.